" />

magAssist was awarded the title of "Venture 100 Future Unicorn"

On December 16, 2021, the CYZONE 100 FUTURE UNICORNS Summit was held in Shanghai. "CYZONE 100 FUTURE UNICORNS" is focused on discovering companies that have been established within 10 years in the rapid growth stage, and have a high potential to be promoted to the ranks of unicorns in the future. It is intended to help accelerate the expansion of unicorns in China, the commercialization of emerging technologies, and the promotion of the Health China 2030 plan.

With its outstanding performance in five dimensions: innovation, growth rate, financing ability, management team and development prospect, magAssist was selected as one of the "2021 CYZONE 100 Future Unicorns" among more than 700 outstanding companies.

At the CYZONE 100 Future Unicorn Summit,co-founder Shaoyen Yang was invited to share the theme of "The Golden Decade of Heart Failure Treatment".

magAssist was awarded the title of

Shaoyen Yang in the speech

Shaoyen Yang mentioned that these years are called the golden decade of heart failure. The reason for the name is that the awareness level of patients, doctors and even the country has reached a crossover point. Healthcare professionals and clinicians are aware that heart failure can be solved by blood pumps; society is progressively richer and nationals have certain financial abilities and are willing to use these treatments to prolong life; capital is also willing to invest, plus the attention and support from the state; as R&D personnel, they have accumulated enough technology to solve this problem, so that they can finally stand on this stage and let this matter, which is on the right historical track, to be developed.

Cardiovascular disease has become one of the most deadly diseases worldwide. A variety of diseases such as hypertension, valve disease and coronary artery disease can affect the pumping function of the heart. There are approximately 330 million cardiovascular patients in China, and 13.7 million of them are likely to develop progressive heart failure. A conservative estimate of 600,000 patients will be in the end stage, and most of them will die while waiting for a transplant because of a severe shortage of heart donors and a serious gap between supply and demand. Meanwhile, acute heart failure, or even cardiogenic shock, can occur in large myocardial infarction, after extracardiac surgery, or even in healthy people under infection, trauma, and overexertion, and the current treatments for cardiogenic shock caused by various etiologies are not yet available in China to achieve better clinical results.

Several classic types of artificial hearts include implantable artificial hearts, which provide transitional treatment for heart transplantation in end-stage heart failure; surgically cannulated extracorporeal artificial hearts, which provide life support for each acute heart failure episode throughout heart failure (early, progressive, and end-stage patients); and percutaneous ventricular assist device, which are used to maintain blood flow stability during high-risk PCI procedures.

Different artificial hearts are needed to handle different situations, because each artificial heart is a culmination of engineering, and each product is a combination of multiple needs. There is no one-for-all product, but always a certain balance of trauma, flow and support time to match a certain group or a certain medical scenario.

In general, magAssist hopes to build a multi-organ extracorporeal life support platform including artificial heart, artificial lung and other organs. We have started our journey from lifesaving technology for heart failure, and we aim to cover the clinical needs in acute extracorporeal life support scenarios. With solid technology of artificial hearts, we are able to provide solutions for doctors and patients in ICU or any other acute life support scenarios.

E-mail     Share on Linkedin     Share on Facebook